References
- Yao JC , Meric-BernstamF, LeeJJ, EckhardtSG. Accelerated approval and breakthrough therapy designation: oncology drug development on speed?Clin. Cancer Res.19(16), 4305–4308 (2013).
- Abrams J , ConleyB, MooneyMet al. National Cancer Institute’s Precision Medicine Initiatives for the new National Clinical Trials Network. Am. Soc. Clin. Oncol. Educ. Book2014, 71–76 (2014).
- Mullard A . Learning from exceptional drug responders. Nat. Rev. Drug Discov.13(6), 401–402 (2014).
- Brannon AR , SawyersCL. ’N of 1’ case reports in the era of whole-genome sequencing. J. Clin. Invest.123(11), 4568–4570 (2013).
- Subbiah V , BrownRE, McGuireMFet al. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin’s lymphoma. Oncotarget5(1), 95–102 (2014).
- Iyer G , HanrahanAJ, MilowskyMIet al. Genome sequencing identifies a basis for everolimus sensitivity. Science338(6104), 221 (2012).
- Subbiah V , WestinSN, WangKet al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J. Hematol. Oncol.7(1), 8 (2014).
- Wagle N , GrabinerBC, Van AllenEMet al. Activating mTOR mutations in a patient with an extraordinary response on a Phase I trial of everolimus and pazopanib. Cancer Discov.4(5), 546–553 (2014).
- Al-Ahmadie H , IyerG, HohlMet al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlie outlier response to cancer therapy. Cancer Discov.4(9), 1014–1021 (2014).
- Subbiah V , NaingA, BrownREet al. Targeted morphoproteomic profiling of Ewing’s sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS ONE6(4), e18424 (2011).
- Jiang Y , SubbiahV, JankuFet al. Novel secondary somatic mutations in Ewing’s sarcoma and desmoplastic small round cell tumors. PLoS ONE9(8), e93676 (2014).
- Jiang Y , JankuF, SubbiahVet al. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget4(6), 884–889 (2013).
- Subbiah V , BrownRE, BuryanekJet al. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol. Cancer Ther.11(11), 2541–2546 (2012).
- Oechsle K , HoneckerF, ChengTet al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann. Oncol.22(12), 2654–2660 (2011).
- Feldman DR , TurkulaS, GinsbergMSet al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest. New Drugs28(4), 523–528 (2010).
- Subbiah V , Meric-BernstamF, MillsGBet al. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to sunitinib (Sutent®) a VEGFR2/PDGFRss/c-kit/FLT3/RET/CSF1R inhibitor in a Phase II trial. J. Hematol. Oncol.7(1), 52 (2014).
- Sheridan C . Cancer centers zero in on exceptional responders. Nat. Biotechnol.32(8), 703–704 (2014).